secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001683168-22-004874
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback
--------------------------------------------------------------------------------

- Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.
- Net loss of ~$4.2M ($0.27 per share) compared to net loss of $3.6M ($2.45 per share) in prior year.
- Operating expenses increased to ~$4.4M from $3.6M, mainly due to Nasdaq listing and $90M capital raises.
- Board authorized up to $10M share repurchase program, to begin after release of preliminary results.
- CEO says company expects to begin two-phase pig study, the last major FDA requirement for phase 2b LAPC trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/0001683168-22-004874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-004874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer